Correction to ‘Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system’
{"title":"Correction to ‘Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system’","authors":"","doi":"10.1111/hiv.70274","DOIUrl":null,"url":null,"abstract":"<p>\n <span>Zhang, L</span>, <span>Chen, L</span>, <span>Tang, J</span>, et al. <span>Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system</span>. <i>HIV Med.</i> <span>2026</span>; <span>27</span>(<span>5</span>): <span>749</span>–<span>760</span>. doi:10.1111/hiv.70205\n </p><p>In the version of this article initially published, the funding information was incomplete. The correct version is as follows:</p><p>The author(s) declare that financial support was received for the research and/or publication of this article. This study was funded by the Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital (2022-PUMCH-D-008), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-037), the National Key Technologies R&D Program for the 13th Five-year Plan (2017ZX10202101-001), the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) (2025-12M-XHZY-002) and the Peking Union Medical College Hospital Talent Cultivation Program (Category A) (ULJ03044).</p><p>We apologize for this error.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 8","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70274","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hiv.70274","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Zhang, L, Chen, L, Tang, J, et al. Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. HIV Med.2026; 27(5): 749–760. doi:10.1111/hiv.70205
In the version of this article initially published, the funding information was incomplete. The correct version is as follows:
The author(s) declare that financial support was received for the research and/or publication of this article. This study was funded by the Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital (2022-PUMCH-D-008), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-037), the National Key Technologies R&D Program for the 13th Five-year Plan (2017ZX10202101-001), the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) (2025-12M-XHZY-002) and the Peking Union Medical College Hospital Talent Cultivation Program (Category A) (ULJ03044).
期刊介绍：
HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
